Publications in collaboration with researchers from McMaster University (12)

2023

  1. Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trials

    Thrombosis Research, Vol. 230, pp. 27-32

2022

  1. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

    The Lancet Oncology, Vol. 23, Núm. 7, pp. e334-e347

  2. Development of an international standard set of outcome measures for patients with venous thromboembolism: an International Consortium for Health Outcomes Measurement consensus recommendation

    The Lancet Haematology, Vol. 9, Núm. 9, pp. e698-e706

  3. Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial

    The Lancet Haematology, Vol. 9, Núm. 8, pp. e594-e604

2020

  1. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update

    Journal of Clinical Oncology, Vol. 38, Núm. 5, pp. 496-520

2019

  1. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

    The Lancet Oncology, Vol. 20, Núm. 10, pp. e566-e581

2018

  1. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism

    American Journal of Medicine, Vol. 131, Núm. 4, pp. 430-437

2015

  1. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014

    Journal of Clinical Oncology, Vol. 33, Núm. 6, pp. 654-656

2013

  1. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

    Journal of Clinical Oncology, Vol. 31, Núm. 17, pp. 2189-2204

2011

  1. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials

    The Lancet, Vol. 378, Núm. 9793, pp. 771-784

  2. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials

    The Lancet, Vol. 378, Núm. 9793, pp. 771-784

2004

  1. Compliance with recommended prophylaxis for venous thromboembolism: Improving the use and rate of uptake of clinical practice guidelines

    Journal of Thrombosis and Haemostasis, Vol. 2, Núm. 2, pp. 221-227